Compare SoundHound AI Inc (SOUN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoundHound AI Inc vs Viatris Inc — how do they compare? SoundHound AI Inc trades at $5.39 (market cap $2.45B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 8.2× SoundHound AI Inc's market cap, and Viatris Inc pays a 2.75% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SoundHound AI Inc for 23 Days and Viatris Inc for 57 Days on average.
| SOUN | VTRS | |
|---|---|---|
Market Cap | $2.45B | $20.03B |
Volume | 16,881,989 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $21.40 | $18.27 |
52-Week Low | $5.52 | $9.74 |
Typical Hold Time | 23 Days | 57 Days |
Enterprise Value | $2.25B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoundHound AI (SOUN) trades at $5.395, down 4.17% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth ($169M in 2025, $203M projected for 2026) but deep net losses (-$14M in 2025, -$137M projected). Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices, positioning for voice AI market growth.
Outlook is mixed: analyst consensus is bullish (75% buy ratings, $9.33 target) on growth prospects, but high valuation (P/S 11.41) and persistent losses pose risks. Key opportunities include market expansion and strategic deals; risks center on profitability, integration challenges, and competitive pressures in the AI sector.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
